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Abstract
Background—Breast cancer patients’ misunderstanding of their systemic cancer recurrence risk 
has consequences on decision-making and quality of life. Little is known about how women derive 
their risk estimates.
Methods—Using Los Angeles and Georgia’s SEER registries (2014–2015), a random sample of 
early-stage breast cancer patients was sent surveys about 2–3 months after surgery (N=3930, RR 
68%). We conducted inductive thematic analysis of open-ended responses about why women 
chose their risk estimates in a uniquely large sub-sample (N=1754). Clinician estimates of 
systemic recurrence risk were provided for patient subgroups with DCIS and with low, 
intermediate, and high-risk invasive disease. Women’s perceived risk of systemic recurrence (0–
100%) was categorized as overestimation, reasonably accurate estimation, or underestimation (0% 
for invasive disease) and was compared across identified factors and by clinical presentation.
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Results—Women identified 9 main factors related to their clinical experience (e.g., diagnosis and 
testing; treatment) and non-clinical beliefs (e.g., uncertainty; spirituality). Women who mentioned 
at least one clinical experience factor were significantly less likely to overestimate their risk (12% 
vs. 43%, p<.001). Most women who were influenced by “communication with a clinician” had 
reasonably accurate recurrence estimates (68%). “Uncertainty” and “family and personal history” 
were associated with overestimation, particularly for women with DCIS (75%; 84%). “Spirituality, 
religion, and faith” was associated with underestimation of risk (63% vs. 20%, p<.001).
Limitations—The quantification of our qualitative results is subject to any biases that may have 
occurred during the coding process despite rigorous methodology.
Conclusions—Patient-clinician communication is important to breast cancer patients’ 
understanding of their numeric risk of systemic recurrence. Clinician discussions about recurrence 
risk should address uncertainty and relevance of family and personal history.
Introduction
Women diagnosed with breast cancer almost always want information about their risk of 
systemic disease recurrence following treatment.1–3 Since early-stage breast cancer therapy 
is designed to prevent an incurable, distant metastatic recurrence, reasonable understanding 
of recurrence risk affects patients’ ability to participate in shared decision-making during the 
treatment phase4–6 and also impacts their quality of life during survivorship.4, 7, 8 Patient-
clinician discussions about systemic recurrence risk can be challenging, especially for 
women with lower health literacy, lower numeracy skills, or considerable anxiety or worry 
post-diagnosis.7, 9–12 Previous research has shown that many women overestimate their 
recurrence risk after treatment,7, 11, 12 while other women underestimate their risk, including 
a substantial minority of women with invasive disease who believe they have zero risk.11, 12
Although many studies have documented that women do not understand their risk after 
treatment, few have examined what influences women’s perceptions of their recurrence risk. 
Of these, one focused on local recurrence and found beliefs were primarily related to weight 
and lifestyle behaviors (e.g., diet, exercise and tobacco use).13 In studies focused on 
recurrence more generally, women mentioned estrogen replacement therapy as a possible 
contributor to recurrence,14, 15 while prayer, weight, lifestyle behaviors, and a positive 
attitude were thought to help prevent recurrence.16–19 Unfortunately, these studies have been 
limited by relatively small sample sizes in non-diverse populations and have not specifically 
focused on what influences the development of numeric risk estimates. A better 
understanding of the factors that influence these estimates would provide a foundation for 
improved patient-clinician risk communication interventions.
To provide a more comprehensive understanding of how women derive their recurrence risk 
perceptions, this study used inductive thematic analysis to identify factors that influenced 
early-stage breast cancer patients’ numeric risk estimates in a large, diverse population-
based sample. We then explored whether the factors women mentioned differed by clinical 
presentation and/or by understanding of recurrence risk.
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Methods
Study Population
The iCanCare Study, a large, diverse, population-based survey study of women with 
favorable prognosis breast cancer, accrued women aged 20–79 with newly diagnosed breast 
cancer (ductal carcinoma in situ, DCIS and stages I–II) as identified by rapid reporting 
systems from the Surveillance Epidemiology and End Results (SEER) registries of Georgia 
and Los Angeles County in 2014–15. Black, Asian, and Hispanic women were oversampled 
in Los Angeles.20
Data Collection
Patients were sent surveys approximately 2–3 months after surgery. The median time 
between SEER date of diagnosis and receipt of the survey was 7 months. We provided a $20 
cash incentive and used a modified Dillman method for patient recruitment, as done in prior 
work.20, 21 All materials were sent in English and Spanish to those with Spanish surnames.20 
Survey responses were merged with clinical data from SEER. The study was approved by 
the Institutional Review Boards of the University of Michigan, University of Southern 
California, Emory University, the Committee for the Protection of Human Subjects, and the 
California Cancer Registry. Please note that our funding source, the National Cancer 
Institute (NCI), had no role in this study.
Questionnaire Design and Content
Patient questionnaire content was guided by a conceptual framework, research questions, 
and hypotheses. We chose established measures when available and developed new 
measures, when necessary, drawing from the literature and our prior research.22–24 We used 
standard techniques to assess content validity, including expert review, cognitive pre-testing, 
and pilot studies in clinic populations.25, 26
The iCanCare survey was divided into a number of sections including items/measures on 
quality of life, diagnosis, testing and treatment for breast cancer, decision-making, 
communication, support from others, thoughts and feelings, family history, and 
demographics. This paper focuses on items from the section entitled “thoughts and 
feelings.” This section was devoted to patient perception of risk of recurrence, doctor 
communication about risk, and worry about recurrence. Previous papers from our group 
have focused on doctor communication11 and worry.7 Measures specific to this current sub-
study are listed below.
Measures
Perceived risk of systemic recurrence—As part of the survey, women were asked two 
questions about their perceptions of their numeric recurrence risk. First, they were asked to 
give a numeric estimate from 0 to 100% in response to the following question: “After 
receiving all the planned treatments, what do you think is the chance that your cancer will 
spread to other parts of your body within 10 years?” Secondly, women were asked an open-
ended follow-up question, “Why did you pick this number?” Some women had completed 
all primary treatment when the survey was sent to them, while others were still receiving 
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radiation and/or chemotherapy. As a result, we chose to include the phrase “after receiving 
all the planned treatments” in the first question so that all women were using the same 
context in making their recurrence risk estimate.
Data Analysis
Part I: Identifying factors that influenced women’s numeric estimates of 
systemic recurrence risk—A primary analyst with qualitative research training 
thematically coded27 women’s responses to the question, “Why did you pick this number?” 
(N=1754).28 The responses were coded without knowledge of the numeric response that 
women provided in the preceding question. Each woman’s response could be assigned to 
more than one code, as some women mentioned multiple reasons for selecting their numeric 
estimates. A second analyst independently reviewed 1000 randomly selected open-ended 
survey responses. There was high concordance between the codes identified by the primary 
and secondary data analysts; the secondary analyst did not identify any new codes and small 
discrepancies were resolved though discussion. A study co-investigator with training in 
qualitative methodology held regular meetings with the two analysts to discuss the emerging 
factors identified by women and to make adjustments to the codes as needed.
Once there was a consensus that theoretical saturation had been reached, a final codebook 
was decided upon, and the primary analyst completed the coding/recoding utilizing the 
following factor codes: diagnosis and testing; treatment; uncertainty; personality traits and 
emotions; communication with a clinician; current and future health; spirituality, religion, 
and faith; family and personal history; statistics, research, and stories of others; and other 
(Table 2 provides factor code descriptions and examples). Two of the codes had valence that 
should be noted. “Personality traits and emotions” included responses that indicated both 
positive and negative traits and emotions; women may have mentioned something positive 
(e.g., “positive thinking”), something neutral (e.g., “just a feeling”), or something negative, 
including mentions of fear of recurrence (e.g., “just worry about it coming back”). “Family 
and personal history” included both respondents who mentioned having the presence of a 
family and/or personal history of cancer and those who mentioned the absence of a family 
and/or personal history of cancer. Additionally, there were two different subcategories of 
“uncertainty.” It included women who were uncertain due to a lack of knowledge regarding 
recurrence risk (e.g., “I don’t know,” “I’m unsure”) and women who were uncertain due to 
their attitude that recurrence, or life in general, is unpredictable (e.g., “always a chance,” 
“50/50”).
As a final step to test for interrater reliability, the secondary analyst independently coded a 
random selection of 100 responses using the final codebook. There was 91% interrater 
agreement after comparison. As percent agreement may overestimate coding consistency 
between two raters,29, 30 we used further discussion about the coding process to confirm 
shared interpretation of the codes. Afterwards, minor modifications were made where 
necessary, and coding adjusted if relevant for all respondents.
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Part II: Assessing the relationship between identified factors and patient 
understanding of risk
Clinicians’ estimates of systemic recurrence risk: According to practice guidelines and 
the published literature,31 and in consultation with breast cancer physician co-investigators 
(R.J., A.W.K.), we used stage, histology, and biology from SEER to estimate systemic 
recurrence risk for patient sub-groups following treatment (surgery, radiation, 
chemotherapy). Women were considered to have almost no risk of systemic recurrence if 
SEER data indicated stage 0 (DCIS); low risk of systemic recurrence (<10% risk of systemic 
recurrence) if SEER data indicated stage IA, estrogen receptor (ER)-positive, HER2-
negative, tumor grade 1–2, and tumor genomic profiling with the 21-gene recurrence score 
(RS) either not done or RS 0–10 32; intermediate risk of systemic recurrence (<20% risk of 
systemic recurrence) if SEER data indicated stage IA, ER-positive, HER2-negative, tumor 
grade 1–2, and RS recurrence score >10; or stage IA, ER-positive, HER2-negative, and 
tumor grade 3+; or stage IB or IIA, ER-positive, HER2-negative, with any tumor grade and 
any RS status; or high risk of systemic recurrence (<40% risk of systemic recurrence) if 
SEER data indicated stage IIB, ER-negative, and/or HER2-positive.
Categorizing patients’ understanding of systemic recurrence risk: We then compared 
women’s perceived recurrence risk with their clinically estimated recurrence risk, 
categorizing each woman into one of three perceived risk sub-groups: underestimation, 
reasonably accurate estimation, and overestimation of systemic risk of recurrence after 
treatment. Any woman with invasive disease who responded that her risk of systemic 
recurrence was 0% was placed in the underestimation risk group, as 0% represents 
substantial underestimation of recurrence risk.31 The overestimation risk group included 
women with DCIS who reported perceived risk as greater or equal to 10%, women with low-
risk invasive breast cancer who reported perceived risk as greater or equal to 20%, women 
with intermediate-risk invasive breast cancer who reported perceived risk as greater or equal 
to 30%, and women with high-risk invasive breast cancer who reported perceived risk as 
greater or equal to 50%. All remaining women were put in the reasonably accurate risk 
group; this included women with DCIS who wrote their risk of systemic recurrence was 0%, 
as these women have almost no systemic recurrence risk. Women in the intermediate-risk 
and high-risk invasive groups were subsequently combined into a “higher-risk invasive” 
group as their findings yielded similar patterns.
Identifying factors to compare by understanding of risk and clinical presentation: After 
comparing women’s understanding of risk by which factor (final code) influenced their 
estimates, we selected the factors that had the strongest associations with underestimation, 
reasonably accurate estimation, or overestimation to be further examined by clinical 
presentation.
All statistical comparisons were conducted on the qualitative results using chi-squared tests.
Results
We identified 3930 women with breast cancer from the SEER registries: 258 were later 
considered ineligible due to a prior breast cancer diagnosis or stage III or IV disease; 
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residing outside the SEER registry area; or being deceased, too ill, or unable to complete a 
survey in Spanish or English. Of the 3672 eligible women, 2502 (68%) patients responded, 
and 1172 refused to participate or did not return mailed surveys even after follow-up efforts. 
Of the 2502 respondents, 748 women were excluded from this sub-study: 478 women did 
not answer both survey questions about numeric risk of systemic recurrence, 87 women had 
insufficient information to determine their understanding of risk due to missing clinical 
information from SEER, and 183 women had a very high recurrence risk, which made them 
outside of the primary focus of the iCanCare Study, which aims to observe women with 
favorable prognoses. Thus, the final study sample was 1754 women.
The study design oversampled invasive cancer patients and nonwhite patients, and had 
significantly lower response rates from nonwhite patients and Georgia residents. The 478 
women who did not answer the questions about numeric recurrence risk were significantly 
more likely to be older, nonwhite, and with lower educational status. Weights were 
developed to account for these differences and all analyses were repeated using these 
weights. All significant comparisons below remained significant when weights were used.
Table 1 shows characteristics of the study sample. The majority of women were 50 years or 
older (80%) and had some college education (71%). Additionally, nearly half were non-
white: 9% were Asian, 17% non-Hispanic Black, and 18% Latina. Most women had no 
family history of breast cancer (96%), and 22% had a diagnosis of DCIS (stage 0) while 
78% had invasive disease (stages I–II). Almost two-thirds of women had lumpectomy 
(63%), with the remainder divided equally between unilateral and bilateral mastectomy. 
Approximately half of the sample had radiation and about one quarter had received 
chemotherapy.
Table 2 provides descriptions of the 9 main factors identified by women and “other” (the 
final codes) and representative examples of answers to “why did you pick this number?” 
(N=1754). 68% of women mentioned one factor, 24% mentioned two factors, and 8% 
mentioned three or more factors. Each factor was mentioned with similar frequency across 
the clinical presentation sub-groups (see Supplementary Table 1).
Figure 1 displays how women’s understanding of their risk of systemic recurrence varied by 
the factors used to derive risk estimates. Because women could have mentioned more than 
one reason for their estimates, the sum of the number of women who mentioned each factor 
is greater than the analytic sample. The two most common factors were “diagnosis and 
testing” and “treatment,” which influenced 27% and 22% of women, respectively; they were 
the two most common factors mentioned irrespective of clinical presentation. Note that 
“other” is not included in Figure 1 as 96% of women who mentioned something coded as 
“other” also mentioned one of the 9 main factors.
Across the entire sample we found that four factors—“communication with a clinician,” 
“spirituality, religion, and faith,” “uncertainty,” and “family and personal history” — had 
very strong associations with women’s understanding of risk (i.e., with either reasonably 
accurate estimation, underestimation, or overestimation). For example, women who 
mentioned being influenced by “communication with a clinician” were significantly more 
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likely to have a reasonably accurate understanding of their recurrence risk (68% vs. 46%, 
p<.001). Women who were influenced by “spirituality, religion, and faith,” were more likely 
to underestimate their risk as zero percent (63% vs. 20%, p<.001). Conversely, women who 
were influenced by “uncertainty” and/or “family and personal history” were more likely to 
overestimate their risk (54% vs. 22%, p<.001 and 56% vs. 24%, p<.001, respectively). 
Given that we had used a numeric scale (0 to 100%), we further explored the 158 women out 
of 1754 (9%) who said 50%. When we re-analyzed our results with these 158 women 
removed from the sample, all significant findings remained significant. Two-thirds of 
women who estimated 50% as their recurrence risk wrote a response as to “why” that was 
coded “uncertainty” (N=95, 42%) and/or “family and personal history” (N=53, 24%).
As “family and personal history” had valence, we completed a sensitivity analysis of all 
women who mentioned it in their response. Among women who wrote in their response to 
“why did you pick this number” that they had the presence of a family or personal history 
N=143, 90 (63%) overestimated their risk, 43 (30%) were reasonably accurate, and 10 (7%) 
underestimated. Among women who wrote a response indicating the absence of a family or 
personal history N=26, 4 (15%) overestimated, 17 (65%) were reasonably accurate, and 5 
(19%) underestimated their clinically determined risk. Overestimation was significantly 
more likely for women with the presence a family or personal history compared to all other 
women (p<.001). There was not a significant difference for women with the absence of a 
family or personal history compared to all other women (p=.302), though this was a small 
group of women.
We further examined the four factors with very strong associations with women’s 
understanding of risk by clinical presentation to separately observe their influence for 
women with DCIS, low-risk invasive disease, and higher-risk invasive disease (Figure 2).
1. Communication with a Clinician: For women with DCIS and higher-risk 
invasive disease, those who specifically mentioned they were influenced by 
“communication with a clinician” were very likely to have a reasonably accurate 
estimation of their risk (72% and 75%, respectively). This relationship between 
patient-clinician communication and understanding of risk was also strong 
among women with low-risk invasive disease (51%), although a substantial 
minority (29%) of these women underestimated their risk of recurrence.
2. Spirituality, Religion, and Faith: Over 70 percent of the 144 women with 
invasive disease who were influenced by spirituality, religion, and faith 
underestimated their risk as zero percent. In contrast, most (87%) of women with 
DCIS who were influenced by spirituality, religion, and faith were reasonably 
accurate estimators. A majority of these women actually also reported zero 
percent risk (83%), however, as noted earlier, this was categorized as reasonably 
accurate estimation, as women with DCIS do essentially have zero risk of 
systemic recurrence.
3. Uncertainty and 4. Family and Personal History: “Uncertainty” and “family 
and personal history” were associated with considerable overestimation of risk 
for women with all types of clinical presentation, though women with DCIS who 
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mentioned these factors were far more likely to overestimate their numeric risk 
of systemic recurrence (75% and 84%) compared to women with low-risk 
invasive disease (61% and 45%, p<.001) or with higher-risk invasive disease 
(43% and 48%, p<.001).
For final analyses, we collapsed the clinical presentation sub-groups and dichotomized the 
factors women used to derive risk estimates into 2 categories: (1) responses that related to 
some clinical aspect of the current cancer experience (i.e., communication with a clinician, 
diagnosis and testing, and/or treatment) versus (2) no mention of any of these factors (Figure 
3). About half of the women in our sample included some mention of their current cancer 
experience as an influence in their risk perception. Those women who did not mention any 
aspect of their communication with clinicians, clinical diagnosis, testing, or treatment were 
less likely to have a reasonably accurate understanding of their risk of recurrence (38% vs. 
59%, p<.001) and were substantially more likely to overestimate their risk (43% vs. 12%, 
p<.001).
Discussion
Within this large, diverse population-based sample of women with newly diagnosed DCIS 
and early-stage invasive breast cancer, women mentioned a wide variety of clinical and non-
clinical factors that they used to derive their perception of their systemic recurrence risk 
after treatment. While previous studies have also found that many women with breast cancer 
are not accurate in their numeric recurrence risk estimates7, 11–12 and have noted that women 
use factors that are not clinically relevant to recurrence to estimate its likelihood,13–19 
current literature, to our knowledge, has not explored the connections between these two 
elements with an inductive qualitative methodology. Our application of this methodology 
and a large sample size allowed us (1) to comprehensively identify multiple factors that 
influence women’s development of their numeric risk estimates about systemic recurrence 
and (2) to explore the effects of these factors on understanding of risk.
This paper’s findings suggest that clinicians should discuss the true factors that influence 
recurrence risk with their patients. Across all women in this study, those who were 
influenced by a least one factor related to their clinical experience, “diagnosis and testing”; 
“treatment”; “communication with a clinician,” were much more likely to have a reasonably 
accurate understanding of their risk of systemic recurrence than women who were solely 
influenced by other factors. Specifically, mention of “spirituality, religion, and faith” had the 
strongest association with underestimation in our sample of women with DCIS and early-
stage invasive disease, and “uncertainty” and “family and personal history” had the strongest 
associations with overestimation.
One factor, “communication with a clinician” played a particularly positive role for women 
at the extremes of the risk spectrum: those with DCIS or higher-risk invasive disease. Over 
70% of women in each group who mentioned “communication with a clinician” had 
reasonably accurate estimates, consistent with our previous work.11 A considerable 
percentage of women with low-risk invasive disease who mentioned “communication with a 
clinician” actually underestimated their risk. It may be that if clinicians use only qualitative 
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terms such as “low risk,” some patients may incorrectly interpret this to mean “no chance” 
of recurrence.33, 34 Clinician explanations that include both a number as a frame of reference 
along with words may be particularly important for women with low health literacy and/or 
numeracy.11
Women who were influenced by “spirituality, religion, and faith” considered their risk of 
systemic recurrence to not only be low but to be “zero percent,” irrespective of clinical 
presentation. Specifically, for women with invasive cancer, this meant substantially 
underestimating recurrence risk. Other research has found that some women believe that 
prayer and God’s will might help to prevent cancer recurrence.16, 35 Because 
underestimation may be linked to negative behaviors, such as non-adherence to adjuvant 
endocrine therapy or annual mammographic screening, our results suggest that clinicians 
carefully review the importance of closely following survivorship recommendations with 
women, irrespective of religious orientation, explaining that the recommendations have 
relevance regardless of one’s own perceived risk.36–38
Prior research has also shown that some women voice a sense of “uncertainty” about their 
risk of breast cancer or breast cancer recurrence.18, 39 We found that women who mentioned 
uncertainty overwhelmingly overestimated their recurrence risk, especially women with 
DCIS. Others have also reported that women with DCIS may be particularly vulnerable to 
overestimating their risk,7, 12, 40 and our findings provide further insight that uncertainty 
may contribute to this misunderstanding. Additionally, the different forms of “uncertainty” 
reported by women in our study (e.g., “I don’t know,” “always a chance,” “50/50”) support 
the inherent variability of the construct. Mishel’s theory of uncertainty in illness as well as 
work by Han et al. discuss how patients’ uncertainty can relate to the illness and/or the 
health care system and may be due to a lack of knowledge or the unpredictability of the 
situation.41, 42 In our sample, women were more likely to overestimate their risk regardless 
of which subcategory of uncertainty they expressed. When uncertainty is due to a lack of 
knowledge, it may be effectively reduced by simplifying and reorganizing the risk 
information.42 Some uncertainty due to an illness may be irreducible, as even clinicians 
must rely on estimates.41, 42 Clinicians should help women accept the uncertainty inherent in 
predicting disease recurrence without letting it lead to marked inaccuracy in perceptions of 
the magnitude of risk.42, 43
Finally, our finding that family and personal history influences women’s risk estimates is 
consistent with prior studies.44–48 We previously reported that women who had a family 
history of breast cancer were more likely to overestimate their systemic recurrence risk,7 and 
our findings are similar in the present study. However, we expand prior work through finding 
overestimation is more likely not only if women have a family history7 but also if women 
state that their family history influenced the development of their recurrence risk estimate. 
When women have a family or personal history, it may naturally generate feelings of 
increased risk, which for some may be warranted, but for many less so, as family history is 
likely related to patients’ risk of a new cancer not their risk of systemic recurrence.49, 50 
Focused discussions of how family and personal cancer history are relevant to a woman’s 
current cancer experience may help to sort out this complex dynamic.7 Special consideration 
should be given to women with DCIS, as risk overestimation was present in a remarkably 
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large percentage (84%) of these women who mentioned family and personal cancer history, 
and while overestimation of recurrence risk may lead to positive behaviors, such as 
exercising, there is also strong evidence that it may be harmful—breast cancer survivors’ 
overestimation has been associated with worry, anxiety, and a worse quality of life.7,12 Thus, 
clinicians should aim to correct for overestimations of risk while encouraging women to 
develop and/or maintain healthy behaviors. Future research might use the factors we have 
identified in this qualitative analysis to develop closed-ended survey questions in order to (1) 
gain a better understanding of how commonly these factors influence women’s estimates 
and (2) why these factors influence women’s numeric risk estimates.
This study’s strengths include its large, diverse population-based sample and in-depth, 
inductive qualitative methodology. However, there are some potential limitations. Caution is 
necessary when generalizing these findings to regions dissimilar to the two areas from which 
our patients were drawn: Los Angeles and Georgia. Additionally, despite our use of 
investigator triangulation,51 the quantification of the results from our qualitative analysis is 
subject to any biases that remained during the coding process.
We also note limitations with the survey questions. The first question’s use of the term 
“planned treatments” may have been a confounder, and some patients might conflate true 
cancer recurrence (the failure to fully eradicate the cancer, such that it is able to spread) with 
new primary cancer development (eradication of the existing cancer but development of an 
entirely new cancer that spreads). Also, our findings are limited by our use of a numeric risk 
estimate of systemic recurrence, which may not fully represent respondents’ underlying 
understanding of their likelihood of recurrence. Past research has demonstrated that some 
respondents have difficulty generating responses to such questions because they have lower 
numeracy skills. As we have discussed above, some people answer these questions with a 
50% estimate when what they mean by that response is a qualitative sense of uncertainty 
about an uncertain event (i.e., it might happen, or it might not).52 Even among more 
numerate respondents, there is a tendency for individuals to estimate numeric risk in 
clusters, perhaps focusing on the “gist” meaning of a numeric scale (i.e., low versus high) 
rather than truly estimating the underlying likelihood.53 Alternate approaches to measuring 
risk perceptions include providing respondents with a probability scale to use when making 
a numeric estimate,54 focusing on relative risk perceptions (e.g., Dillard)55 or using verbal 
terms (e.g., Berry),56 although the research shows that each of these approaches have their 
own drawbacks.57–58 Thus, while we can conclude that many breast cancer survivors 
misunderstand their numeric recurrence risk, we cannot claim that the only reasons behind 
the underestimation and overestimation shown in this study are the influencing factors that 
we identified, as some of the inaccuracy may have been due to the effects of the numeric 
scale. Future research to evaluate the associations between the factors identified here and 
numeric estimates provided through the use of a probability scale, gist estimates, or relative 
estimates of risk (e.g., questions asking respondents for perceptions of how their risk 
compares to that of the average patient) may yield further insights.
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Conclusion
This study of more than 1700 women enabled a greater understanding of what factors 
influence breast cancer patients’ perceptions of their systemic recurrence risk. To our 
knowledge, this has been the largest study to qualitatively analyze reasons for reporting risk 
of recurrence estimates. Patient-reported communication with a clinician about disease 
recurrence was most commonly associated with patients’ having a reasonable understanding 
of risk. These findings emphasize the importance of cancer clinicians educating patients 
about their systemic cancer recurrence risks, given the documented negative consequences 
of overestimation and underestimation of risk. It also reinforces the need to clarify with 
patients what factors actually do and do not influence recurrence risk, including asking 
patients about how they derive their risk estimates. Priorities moving forward include 
informing clinicians about best practices to present risk information in the challenging 
circumstances of a cancer diagnosis, with a specific focus on uncertainty and family and 
personal cancer history, especially among women with DCIS.
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Figure 1. 
Distribution of factors by patient understanding of risk of systemic recurrence.
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Figure 2. 
Factors that exhibited strong associations with a perceived risk subgroup across the entire 
sample delineated by clinical presentation.
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Figure 3. 
Patient understanding of risk of systemic recurrence based on mention of clinical experience 
factors. Clinical experience factors included “communication with a clinician,” “diagnosis 
and testing,” and “treatment.”
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Table 1
Characteristics of Study Sample, N=1754
Variables Na (%)
Sociodemographic Factors
Age
 Under 50 352 (20%)
 50–65 846 (48%)
 65 and over 556 (32%)
Race
 Asian 163 (9%)
 Non-Hispanic White 956 (55%)
 Non-Hispanic Black 295 (17%)
 Latina 316 (18%)
 Other/Unknown/Missing 24 (1%)
Education
 High school diploma or less 480 (27%)
 Some college or more 1240 (71%)
Clinical Factors
Family History
 No family history of breast cancer 1679 (96%)
 1 or more family member with breast cancer 73 (4%)
SEER Stage
 0 382 (22%)
 I 978 (56%)
 II 392 (22%)
Surgery Type
 Lumpectomy 1096 (63%)
 Unilateral mastectomy 311 (18%)
 Bilateral mastectomy 316 (18%)
Radiation Therapy
 No 797 (45%)
 Yes 927 (53%)
Chemotherapy
 No 1322 (75%)
 Yes 397 (23%)
Comorbidities
 None 1202 (69%)
 1 or more 552 (31%)
aN values for education, family history, SEER stage, surgery type, radiation therapy, and chemotherapy do not sum to the analytic sample N due to 
missingness; accordingly, their percentages may not sum to 100%
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Table 2
Findings from Qualitative Analysis: Final Code Descriptions and Representative Examples
CODE DESCRIPTION EXAMPLES
Diagnosis and Testing Characteristics of the respondent’s breast cancer 
and tests used to better understand the breast 
cancer or the respondent’s risk of cancer
“Cancer was very small.”
“I feel that my breast cancer was diagnosed very early.”
“Oncotype DX.”
“I had DCIS Stage 0.”
Treatment Respondent’s perception of cancer treatments’ 
effectiveness or of healthcare providers’ abilities 
in regard to providing treatment
“I think chemo + radiation took care of all the cancer.”
“Because it was fully removed.”
“I had clear margins”
“Because I trust my Drs.”
Uncertainty Respondent is uncertain herself, perceives cancer 
or life to be unpredictable or uncertain, or 
believes there is a 50/50 chance
“I don’t know.”
“Just a guess.”
“Always a chance.”
“50/50 chance.”
Personality Traits and 
Emotions
Respondent’s personality, emotions, or attitude “Positive thinking.”
“I am trying to be as optimistic as possible.”
“I hope it doesn’t spread.”
“Just worry about it coming back.”
Communication with a 
Clinician
Clinicians’ opinions or comments about the 
respondent’s cancer or information provided by 
clinicians
“It is what I was told.”
“% the doctor said it could come back.”
“What I was given by oncologist.”
“Information from my doctor.”
Current and Future Health How the respondent currently feels as well as her 
lifestyle or surveillance/prevention behaviors
“I have made lifestyle changes.”
“Because I am generally healthy.”
“Because of my age.”
“I get regular check-ups and mammograms.”
Spirituality, Religion, and 
Faith
Any mention of God, religion, or faith “Because of my faith in God.”
“Faith.”
“I pray to God that it does not come back.”
“‘I believe in God’s healing.”
Family and Personal 
History
Past family or personal experiences with cancer 
or the lack thereof, or personal experiences that 
the respondent feels are related to her breast 
cancer
“Family history.”
“No family history.”
“Because on my mother’s side of the family there have 
been several kinds of cancer.”
“Get cancer once, you have a higher risk of getting 
elsewhere.”
Statistics, Research, and 
Stories of Others
Sources of information not explicitly said to be 
from healthcare providers: statistics, research, 
and stories of friends and other non-family 
members
“Based on research I have done.”
“After reading information.”
“I have known people that it has come back in different 
places.”
“That is what stats showed in comparable situation.”
Other A response that is uncommon and does not 
warrant the creation of a new code, and/or does 
not allow clear placement into a code
“Because it’s low.”
“Because that’s what I think.”
(Other miscellaneous responses that were even less 
common)
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